| Drug / Therapy | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg |
| Indication | — |
| Decision Type | Phase 3 |
| Trial Phase | Phase 3 |
| ClinicalTrials.gov | NCT05677490 |
Baxter International Inc. (BAX) operates in the RNA Therapy sector. The current BTS Score is 73 (Grade: B).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The Phase 3 date for mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg by Baxter International Inc. (BAX) is scheduled for November 8, 2028. This is the target date for the FDA to make a decision on this application.
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg is being developed by Baxter International Inc. for the treatment of its target indication. It is currently in Phase 3 clinical trials.
If mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg receives FDA approval, Baxter International Inc. (BAX) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 3 date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for BAX on DilutionWatch at dilutionwatch.com/stock/BAX.html.
You can view the full BiotechSigns company profile for Baxter International Inc. (BAX) at biotechsign.com/app/company/BAX, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSigns is not a registered investment advisor.